Compare Novartis with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ELDER PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ELDER PHARMA NOVARTIS/
ELDER PHARMA
 
P/E (TTM) x 510.0 -0.2 - View Chart
P/BV x 29.6 0.1 29,314.8% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NOVARTIS   ELDER PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ELDER PHARMA
Jun-14
NOVARTIS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs758380 199.5%   
Low Rs579188 308.0%   
Sales per share (Unadj.) Rs228.4491.2 46.5%  
Earnings per share (Unadj.) Rs31.7-3.2 -997.5%  
Cash flow per share (Unadj.) Rs32.814.4 227.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.1376.5 78.9%  
Shares outstanding (eoy) m24.6920.54 120.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.90.6 506.3%   
Avg P/E ratio x21.1-89.3 -23.6%  
P/CF ratio (eoy) x20.419.7 103.5%  
Price / Book Value ratio x2.20.8 298.3%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5055,833 282.9%   
No. of employees `0000.7NA-   
Total wages/salary Rs m1,4452,179 66.3%   
Avg. sales/employee Rs Th8,441.3NM-  
Avg. wages/employee Rs Th2,163.6NM-  
Avg. net profit/employee Rs Th1,173.1NM-  
INCOME DATA
Net Sales Rs m5,63910,089 55.9%  
Other income Rs m1,718257 669.6%   
Total revenues Rs m7,35710,346 71.1%   
Gross profit Rs m-63-792 7.9%  
Depreciation Rs m25361 7.0%   
Interest Rs m552,756 2.0%   
Profit before tax Rs m1,575-3,653 -43.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m792125 632.5%   
Profit after tax Rs m784-65 -1,199.1%  
Gross profit margin %-1.1-7.8 14.1%  
Effective tax rate %50.3-3.4 -1,466.8%   
Net profit margin %13.9-0.6 -2,145.4%  
BALANCE SHEET DATA
Current assets Rs m9,5229,240 103.0%   
Current liabilities Rs m3,2969,998 33.0%   
Net working cap to sales %110.4-7.5 -1,470.1%  
Current ratio x2.90.9 312.6%  
Inventory Days Days3746 79.1%  
Debtors Days Days2860 47.4%  
Net fixed assets Rs m4610,124 0.5%   
Share capital Rs m123206 60.0%   
"Free" reserves Rs m7,2135,582 129.2%   
Net worth Rs m7,3367,734 94.9%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m11,10522,882 48.5%  
Interest coverage x29.5-0.3 -9,064.1%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 115.2%   
Return on assets %7.611.8 64.2%  
Return on equity %10.7-0.8 -1,264.0%  
Return on capital %22.222.3 99.6%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m61307 19.8%   
Fx outflow Rs m3,630125 2,897.2%   
Net fx Rs m-3,570181 -1,968.9%   
CASH FLOW
From Operations Rs m1,61011,754 13.7%  
From Investments Rs m687-561 -122.6%  
From Financial Activity Rs m-2,677-6,762 39.6%  
Net Cashflow Rs m-3804,432 -8.6%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 7.5 26.7%  
FIIs % 1.6 16.8 9.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 36.1 59.6%  
Shareholders   41,647 16,479 252.7%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 23, 2019 01:01 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS